Featuring perspectives from Dr Spencer Bachow, Dr Bhavana (Tina) Bhatnagar, Dr Jennifer Crombie, Dr Manali Kamdar and Ms Alexandra Lynch, co-moderated by Dr Bachow and Dr Bhatnagar, including the following topics:
- Introduction and Overview of Bispecific Antibodies in the Clinic (0:00)
- Current and Future Role of Bispecific Antibodies in Non-Hodgkin Lymphoma — Dr Kamdar (15:58)
- Case: A man in his early 60s with diffuse large B-cell lymphoma (DLBCL) receives glofitamab (42:40)
- Case: A woman in her early 80s with follicular lymphoma (FL) receives mosunetuzumab (51:50)
- Mitigation and Management of Cytokine Release Syndrome (CRS) and Other Toxicities Associated with Bispecific Antibodies — Dr Crombie (1:00:39)
- Case: A woman in her early 80s with DLBCL receives glofitamab (1:18:50)
- Case: A woman in her early 70s with FL receives epcoritamab (1:26:38)
- Outpatient CRS Management in B-Cell Lymphomas — Ms Lynch (1:29:28)
- Case: A woman in her late 40s with FL receives epcoritamab (1:38:33)
- Case: A man in his early 70s with mantle cell lymphoma receives mosunetuzumab (1:46:26)